LILA visionary.art
Pharmakon Complexes Clinical Psychedelic Ritual Complex
CEREMONIAL / SOCIOTECHNICAL COMPLEX · CLINIC ↔ LABORATORY ↔ REGULATOR

Clinical Psychedelic Ritual Complex

Psilocybin · ketamine · MDMA · therapist dyad · eyeshades · music · scales · clinics · regulatory authority

The clinical psychedelic ritual complex is a modern therapeutic and experimental assemblage. Psychoactive compounds are made clinically usable through screening, preparation, a controlled room, trained attendants, music, inward attention, adverse-event procedures, diagnostic categories and repeated measurement. Its dominant contemporary form descends from mid-twentieth-century psycholytic and psychedelic therapy, but it is continually remade by neuroscience, psychotherapy schools, pharmaceutical manufacture, clinic finance, intellectual property and regulatory review. Psilocybin, ketamine and MDMA occupy different pharmacological, experiential and legal positions within this shared apparatus. The name “ritual” here identifies a repeatable, symbolically charged sequence under institutional authority; it does not imply that the clinic is a traditional sacramental lineage (Hartogsohn, 2017; Dumit and Sanabria, 2022; Gukasyan and Nayak, 2022).

Constituents & preparation

Classic serotonergic psychedelic

Psilocybin

4-phosphoryloxy-N,N-dimethyltryptamine · prodrug of psilocin

Psilocybin is dephosphorylated to psilocin, whose psychedelic action is substantially mediated by serotonin 5-HT2A receptor agonism. Contemporary studies usually combine a manufactured capsule with preparatory meetings, a long supervised session and follow-up or integration. The drug day commonly privileges eyeshades, headphones and an inward-directed stance (Johnson, Richards and Griffiths, 2008; Griffiths et al., 2006).

Acute arcUsually 4–6 hours; clinical attendance longerProminentVisual imagery, emotional amplification, autobiographical and mystical-type experienceResearchDepression, end-of-life distress, addictions and other indicationsStatusSchedule I federally in the USA; investigational medicine; regulated adult services in Oregon
Dissociative anaesthetic / rapid-acting antidepressant

Ketamine

R,S-ketamine · S-ketamine / esketamine · R-ketamine / arketamine

Ketamine is an NMDA-receptor channel blocker with anaesthetic, analgesic, dissociative and rapid-antidepressant actions. Downstream glutamatergic, AMPA and synaptic-plasticity mechanisms are actively studied; no single account exhausts its effects. Psychiatric use includes brief monitored intravenous infusions of generic racemic ketamine, intramuscular or lozenge-based ketamine-assisted psychotherapy (KAP), and supervised intranasal esketamine under a distinct pharmaceutical regime (Berman et al., 2000; Zarate et al., 2006; Krystal et al., 2023).

Acute arcRoute-dependent; an IV session is often approximately 40 minutes with 1–2 hours of recoveryProminentDissociation, altered embodiment, spatial/architectural imagery, time distortion, observer perspectiveModelsBiomedical infusion · KAP · psychedelic-dose KPT · Spravato/REMSStatusSchedule III in the USA; generic ketamine is approved as an anaesthetic, not for psychiatric indications; esketamine is approved for specified depressive disorders
Entactogen / empathogen

MDMA

3,4-methylenedioxymethamphetamine · midomafetamine

MDMA acts primarily as a monoamine releaser through serotonin, norepinephrine and dopamine transporters. Its clinical use has centred on trauma-focused work in which reduced fear, increased affiliative feeling and tolerable engagement with traumatic memory are therapeutically recruited. It is pharmacologically and phenomenologically distinct from classic psychedelics, though incorporated into the same assisted-therapy infrastructure (Mitchell et al., 2021; Mitchell et al., 2023).

Acute arcA prolonged clinical day, commonly 6–8 hoursProminentWarmth, trust, emotional openness, somatic memory; imagery possible but less consistently visualResearchPrincipally PTSD within the MAPS/Lykos programmeStatusSchedule I federally in the USA; FDA declined approval in 2024 pending further evidence; restricted psychiatric access in Australia
Ritual media and institutional constituents
Human container

Therapist dyad and medical team

Two attendants—often gender-balanced in older and MAPS-derived protocols—provide continuity and observation. Medical oversight, nursing and emergency access may sit outside the room. The dyad is a historically specific design, not a universal requirement (Brennan et al., 2022).

Attentional technology

Couch, eyeshades and headphones

Reclining posture and reduced visual input direct attention toward imagery, memory and bodily sensation. Removing the ordinary clinic’s desk-and-chair arrangement alters the expected social script of treatment.

Temporal architecture

Curated music

Music marks onset, ascent, peak and return; it supports affect without requiring continuous verbal direction. Helen Bonny’s phase-sensitive programmes at Maryland remain a major ancestor of current playlists (Bonny and Pahnke, 1972; Kaelen et al., 2018).

Narrative work

Preparation and integration

Preparation creates expectations, consent boundaries and coping practices. Later meetings narrate the event and connect it to conduct, relationships and treatment goals. Definitions and evidence for “integration” remain variable (Frymann et al., 2022).

Measurement

Psychometric scales

Symptom, acute-experience and alliance measures translate private experience into endpoints. They enable comparison and regulatory claims while selecting only particular features of the event.

Safety infrastructure

Screening, monitoring and rescue

Medical and psychiatric assessment, consent, vital signs, adverse-event coding and follow-up distinguish research and licensed care from unsupervised use. Risks and exclusions differ substantially by drug (Johnson, Richards and Griffiths, 2008; FDA, 2025).

Preparation as protocol

FormRoom and personnelSpeech / silenceMeasurementGoverning logic
Psilocybin-supported therapyDomesticised research room; one or two guides; medical coverPredominantly inward attention; supportive, usually non-directive interventionsMADRS/HAM-D or indication-specific outcomes; MEQ30, ASC, EDI, CEQOne or a few high-intensity sessions linked to durable change
MDMA-assisted therapyTwo-person therapy team in the MAPS model; long session; overnight support sometimes built into trialsAlternation between inward focus and trauma-oriented dialogueCAPS-5, disability and safety outcomes; alliance and expectancy increasingly scrutinisedDrug plus manualised therapy submitted as a combined treatment system
IV ketamine psychiatryMedical infusion chair or bed; prescriber and monitoring staffOften little psychotherapy during administrationMADRS, HAM-D, QIDS or PHQ-9; blood pressure and dissociation scalesRapid symptom reduction, induction series and maintenance
Ketamine-assisted psychotherapyTherapy room; therapist present; route and intensity vary widelyPsycholytic dialogue, inward immersion, or psychotherapy after acute effectsDepression, anxiety, PTSD, addiction and process measures; weak standardisationPharmacological window plus experiential and relational work
Esketamine / SpravatoCertified healthcare setting; supervised self-administration and observationPsychotherapy is not mandated by the drug labelDepression scores, sedation/dissociation and vital-sign monitoringApproved pharmaceutical product under REMS and repeated clinic attendance

Culture

Clinical territories

Saskatchewan · Prague · Britain · Maryland
1950s–1970s

Hospital psychiatry, alcoholism treatment, psycholytic therapy and Spring Grove/Maryland research developed the room, music and high-dose “psychedelic therapy” forms that still shape current protocols (Dyck, 2005; Oram, 2016).

Menlo Park · IFAS
1961–1965

Myron Stolaroff’s International Foundation for Advanced Study joined engineering culture, creativity research and guided LSD/mescaline sessions. Willis Harman, James Fadiman, Robert Mogar and others worked within its orbit (Oram, 2016).

Underground therapy · California · Russia
1970s–1990s

Leo Zeff transmitted MDMA and other methods through informal therapist networks; Stolaroff later recorded this lineage. In Leningrad/St Petersburg, Evgeny Krupitsky and Andrei Grinenko developed ketamine psychedelic therapy for addiction from the late 1980s (Stolaroff, 2004; Krupitsky and Grinenko, 1997).

Johns Hopkins · Imperial · Zürich · academic centres
2000s–present

Modern psilocybin research rebuilt controlled trials, safety standards, neuroimaging and mystical-experience measurement around academically acceptable indications (Griffiths et al., 2006; Johnson, Richards and Griffiths, 2008).

MAPS network · multinational trial sites
1990s–present

MAPS, founded by Rick Doblin in 1986, coordinated a long campaign to move MDMA from underground therapy into clinical development. Michael and Annie Mithoefer, Marcela Ot’alora, Jennifer Mitchell and many site teams translated that project into manuals and trials.

Infusion clinic · KAP practice · telehealth · REMS centre
2000s–present

Ketamine expanded through multiple economies: generic off-label treatment, psychotherapy practice, venture-funded clinic chains, at-home compounded products and Johnson & Johnson’s proprietary esketamine system (Drabiak, 2025).

History and evidence

Explanatory cosmologies

Psychodynamic / transpersonal: Grof’s cartography organised sessions through biographical, perinatal and transpersonal domains and treated intensified experience as a process with its own direction. This model remains influential among practitioners but is not a consensus neuroscientific account (Grof, 1980).

Peak and mystical experience: Pahnke’s categories—unity, transcendence of time and space, sacredness, deeply felt positive mood, paradoxicality and ineffability—were revised into modern mystical-experience scales. Correlations between such scores and outcome are important, but do not by themselves prove a single causal mechanism (MacLean et al., 2012).

Trauma processing and social safety: MDMA protocols describe an “inner healing intelligence” while research also examines fear extinction, autobiographical memory, affiliation and therapeutic alliance. The manual’s organismic language coexists with biomedical and psychotherapeutic models (Mithoefer, 2017; Mitchell et al., 2021).

Neuroplasticity and critical periods: Contemporary neuroscience frames psychedelic and entactogenic treatments through network dynamics, synaptic plasticity, reopening of learning windows and context-sensitive updating. These mechanisms remain differentiated by compound and are not interchangeable with subjective meaning.

Ketamine’s plural models: The infusion clinic emphasises NMDA blockade, glutamatergic cascades and rapid symptom reduction. KAP adds loosened defences, dissociation, imagery and therapeutic relationship. Krupitsky’s KPT deliberately used an immersive altered state within addiction psychotherapy. Lilly’s “metaprogramming” imagined the mind as a self-modifying biocomputer; it is historically influential in technological psychedelic culture but not a validated treatment mechanism (Krupitsky and Grinenko, 1997; Williams, 2019).

Ritual

The clinical sequence

01

Referral, diagnosis and selection

The person becomes a candidate through a diagnosis, inclusion/exclusion criteria, medication review, risk assessment and consent. This gateway is simultaneously clinical, ethical and administrative.

02

Preparation and alliance

Meetings establish biography, intention, expected effects, touch boundaries, emergency procedures and a response to fear. Expectancy is an active element of the treatment setting, not background noise (Hartogsohn, 2017).

03

Threshold and administration

A capsule, infusion, injection, lozenge or nasal device marks the transition into an altered-state interval. Baseline scores and vital signs establish a before-state against which change will be judged.

04

Inward attention and accompaniment

Eyeshades, headphones, posture and the attendants’ restrained presence support experiential unfolding. MDMA protocols alternate inward attention with dialogue; medical ketamine sessions may be comparatively procedural.

05

Return and observation

Food, conversation, repeated vital signs, mobility checks and discharge criteria restore ordinary social and bodily orientation. A support person or transport plan often mediates return beyond the clinic.

06

Narration, scoring and follow-up

The event becomes a case through integration talk, symptom scales, adverse-event reports and scheduled reassessment. Durable benefit, relapse and retreatment are produced as temporal clinical questions.

Healers, witnesses and authorities

Art and material culture

The room is a designed instrument. Soft furniture, low light, flowers, textiles, landscape or abstract art and an absence of conventional medical clutter domesticise the laboratory. Eyeshades and headphones restrict external input while a playlist supplies a changing emotional landscape. At the same time, the infusion pump, blood-pressure cuff, pulse oximeter, locked drug cabinet, nasal-spray device, therapist manual, adverse-event form and rating tablet display the clinic’s technical and legal obligations. These objects jointly stage intimacy and auditability (Dumit and Sanabria, 2022).

Music is the most developed art form within the protocol. Bonny and Pahnke mapped selections to pre-onset, onset, building, peak, re-entry and return phases. Modern playlists preserve this dramatic arc, but cultural familiarity, lyric content, patient choice and the power of the curator remain active research questions. Kaelen and colleagues’ description of music as a “hidden therapist” captures its perceived agency while also indicating why playlist design cannot be treated as neutral background (Bonny and Pahnke, 1972; Kaelen et al., 2018).

Psychometric liturgy: what the clinic counts

DomainExamplesWhat becomes legibleLimit
DepressionMADRS · HAM-D · QIDS · PHQ-9Clinician-rated or self-reported symptom change, response and remissionCan miss existential, relational and functional changes; repeated scores may shape expectation
TraumaCAPS-5 · PCL-5 · Sheehan Disability ScalePTSD severity and functional impairmentDrug effects can reveal treatment allocation; rater and expectancy controls remain central
Mystical-type experienceMEQ30Unity, transcendence, sacredness, positive mood and ineffabilityA historical construct derived from particular religious-psychological categories
Altered consciousness5D/11D-ASC · 3D-ASC revisedOceanic boundlessness, visionary restructuralisation and anxious ego dissolutionFactor structures vary by drug, population and translation
ProcessEDI · EBI · CEQ · IES/EISEgo dissolution, emotional breakthrough, challenging experience and integrationRetrospective reports are sensitive to narrative framing and demand characteristics
DissociationCADSS · clinician observationDepersonalisation, derealisation and amnesia, frequently used in ketamine researchDissociation can be coded as side effect, mediator, therapeutic material or all three

Visionary phenomenology

Clinical phenomenology is produced by compound, intensity, route, biography, music, expectations and the explanatory language available afterward. The same event may enter a case report as “dissociation,” an integration session as “distance from depression,” and a participant’s account as death, encounter or revelation. The descriptions below distinguish recurring patterns without treating them as inevitable (Hartogsohn, 2017; Gukasyan and Nayak, 2022).

Psilocybin · visual, affective and unitive

Onset · approximately 20–60 minutes

Bodily energy, yawning, nausea, anxiety and sensory intensification may accompany the passage from ordinary attention. Music becomes spatial and emotionally commanding.

Visual restructuring

Closed-eye geometry, saturated colour, organic pattern, faces, landscapes and rapidly transforming symbolic scenes are common. With eyes open, surfaces may breathe or acquire intensified significance.

Biographical and affective depth

Memories can become vivid, embodied and morally charged. Grief, tenderness, shame, terror and gratitude may arrive in sequences that participants later narrate as emotional release or insight.

Unity and sacredness

Boundary-softening, timelessness, unity, noetic conviction and ineffability form the “mystical-type” cluster measured by the MEQ30. High scores correlate with some outcomes but are neither universal nor sufficient for benefit (MacLean et al., 2012).

MDMA · affiliative, somatic and trauma-facing

Onset · approximately 30–60 minutes

Warmth, activation, jaw tension, nausea or apprehension may precede a marked sense of openness. Cardiovascular and temperature effects give the experience a visible medical dimension.

Relational safety

Participants often describe trust, closeness and reduced fear of judgment. The therapist may feel unusually accessible; this intensification makes boundaries and power especially consequential.

Traumatic memory with dual attention

Memories can be revisited while retaining contact with present safety. Alternation between eyeshaded inward work and spoken narration allows image, body sensation and autobiographical meaning to interact.

Vision and aftermath

MDMA is less consistently visual than psilocybin, but dreamlike imagery, symbolic scenes and somatic reliving occur. Fatigue, sleep disruption or low mood may follow; a serene “afterglow” is also reported.

Ketamine · dissociative, spatial and ontologically intense

Psycholytic distance

At lighter intensities, associations loosen, habitual rumination recedes and the body may feel buoyant or remote. A participant can observe emotions with less defensive urgency, allowing dialogue during or soon after the acute phase.

Altered embodiment

Floating, rotation, weightlessness, expansion or contraction of body scale and an observer perspective are characteristic. Touch, gravity and the boundary between body and furniture may become ambiguous.

Spatial and architectural vision

Dark voids, tunnels, chambers, grids, immense machines, cities, landscapes and ecological or cosmic systems can unfold with a compelling three-dimensional logic. Vision may feel travelled through rather than merely seen.

Time collapse and world-loss

Clock time may fragment, loop or disappear. At immersive intensity, ordinary body and room can vanish; some accounts resemble near-death, death–rebirth or disembodied consciousness. These states can be peaceful, terrifying or emotionally neutral.

Return, memory and after-effect

Re-entry may be abrupt or gradual, with dizziness, nausea, confusion and incomplete recall. Rapid relief can precede any articulated insight; in KAP, later narration converts image and dissociation into therapeutic material.

Clinical ambiguity

The same dissociation can be measured as an adverse effect, investigated as a possible mediator and valued as a visionary opening. Current evidence supports ketamine’s rapid antidepressant action more strongly than it supports any single phenomenological mechanism.

> In the province of the mind, what one believes to be true either is true or becomes true within certain limits. — John C. Lilly, Programming and Metaprogramming in the Human Biocomputer (1972). A statement of the experimental constructivism that shaped his isolation-tank and ketamine work; not a clinical efficacy claim.

Salient clinical accounts

Contemporary transformations

Evidence in 2026

established

Ketamine’s rapid antidepressant action: replicated controlled studies support rapid short-term reductions in depressive symptoms, including in treatment-resistant populations. Questions concern durability, maintenance, long-term safety and selection. Generic ketamine’s psychiatric prescribing remains off-label in the USA (Berman et al., 2000; Zarate et al., 2006).

developing

Ketamine-assisted psychotherapy: practice models combine ketamine and therapy in markedly different ways. A 2026 systematic review found reported improvement across eleven studies but high heterogeneity and low overall evidence quality; the three controlled studies did not show significant between-group advantages. This does not negate ketamine’s pharmacological efficacy, but leaves the additive effect and optimal form of psychotherapy unresolved (Simpson et al., 2026).

phase 3

Psilocybin for treatment-resistant depression: peer-reviewed Phase 2 studies showed a rapid effect with adverse events and relapse requiring attention. COMPASS reported that both pivotal COMP360 Phase 3 trials met their primary endpoints in 2025 and 2026; the 2026 results and six-month data were corporate topline disclosures at this page’s review date and require peer-reviewed appraisal (Goodwin et al., 2022; COMPASS Pathways, 2026a; 2026b).

regulatory failure

MDMA for PTSD: two Phase 3 trials reported substantial benefit under a manualised therapy model (Mitchell et al., 2021; 2023). In August 2024 the FDA issued a Complete Response Letter, citing problems with how the treatment should be used, durability and supporting evidence, and requested an additional study. Advisory review also exposed functional unblinding, expectancy, therapist conduct and data-integrity concerns (FDA, 2024a; 2024b).

Regulatory authority and access

Jurisdiction / systemCurrent positionRitual consequence
United States · ketamineKetamine is Schedule III and FDA-approved as an anaesthetic; racemic psychiatric use is off-label. Compounded forms are not FDA-approved for psychiatric treatment.Prescribers can build divergent infusion and KAP practices without a single federally approved psychotherapy protocol. FDA warned in 2023 about compounded and at-home products, including sedation, dissociation, blood-pressure, respiratory and abuse risks where monitoring is inadequate (FDA, 2023).
United States · esketamineSpravato is approved for treatment-resistant depression, including monotherapy under the 2025 label, and for depressive symptoms in adults with MDD with acute suicidal ideation or behaviour in conjunction with an oral antidepressant.REMS requires certified settings, supervised administration and at least two hours of observation. The approved ceremony is repeated, medicalised and product-specific; psychotherapy is optional rather than a labelled component (FDA, 2025; 2019).
United States · MDMASchedule I; no approved medical use. FDA’s 2024 Complete Response Letter for NDA 215455 requested further study.The regulator had to assess a drug-plus-therapy package while its drug jurisdiction and psychotherapy oversight fit imperfectly together.
United States · psilocybinSchedule I federally; investigational drug development continues. Oregon operates a state-licensed adult service system.Oregon requires preparation, supervised administration and offers integration through licensed facilitators at licensed centres; it does not require a prescription or medical referral and is not equivalent to FDA-approved treatment (OHA, 2023).
AustraliaSince July 2023, authorised psychiatrists may access MDMA for PTSD and psilocybine for treatment-resistant depression under the Authorised Prescriber system; products remain unapproved therapeutic goods and safeguards were revised in 2026.Psychiatric specialist authority, human-research ethics review, controlled supply and reporting requirements define access; costs are generally borne privately because products are not PBS-listed (TGA, 2026).

Clinic economies

Ketamine makes the contemporary economy especially visible. An inexpensive, off-patent generic molecule supports fee-for-service infusion clinics and psychotherapy practices; proprietary esketamine supports a reimbursable product with certification and repeated monitoring; telehealth firms have marketed compounded oral ketamine for home use. These models distribute cost, clinical attention and liability differently. The infusion model can minimise psychotherapy; KAP sells extended professional time; the esketamine model ties access to a branded device and REMS-certified site. Long-term maintenance may turn an acute intervention into recurring clinic attendance (Drabiak, 2025; FDA, 2023).

Psilocybin and MDMA development is labour-intensive because the session occupies most of a working day and may require two professionals plus preparation and follow-up. Developers therefore experiment with group preparation, digital monitoring, shortened compounds, specialist centres and therapist-training franchises. The resulting economics can restrict access even when the active molecule is inexpensive. Australia explicitly warns that its unapproved MDMA and psilocybine treatments are not PBS-funded; Oregon service prices are similarly separated from ordinary insurance medicine (TGA, 2026; OHA, 2023).

Patents, proprietary protocols and prior art

Psilocybin: COMPASS Pathways has obtained patents concerning crystalline forms of synthetic psilocybin and sought claims over treatment environments and methods. Critics and prior-art projects argue that features such as soft furniture, music, eyeshades and supportive attendants were documented in older clinical and underground practice. The dispute concerns novelty and control over a protocol as much as ownership of a molecule (Gerber et al., 2021; Marks, 2021).

Ketamine: racemic ketamine is generic, while esketamine, nasal delivery, formulations and indication-specific methods support newer intellectual property and regulatory exclusivity. The market therefore stratifies one chemical lineage into cheap generic, compounded and branded products with different evidence and oversight.

MDMA: MDMA itself is an old compound and cannot be newly monopolised as such. Commercial value accumulates around manufacture, formulation, therapeutic methods, data, training, trademarks and regulatory exclusivity. MAPS’ non-profit campaign and its public-benefit/corporate successors demonstrate how movement infrastructure can become a pharmaceutical development organisation.

Ethics, labour and contested authority

boundary

Touch and intimacy: altered suggestibility, dependency and affiliative intensity make informed consent and boundary governance central. Touch policies should be specific, revocable and documented; evidence that supportive touch improves outcome remains limited (Bender et al., 2025).

method

Blinding and expectancy: obvious psychoactive effects can reveal allocation to participants and staff. Active placebos, independent raters and expectancy measures mitigate but do not eliminate this problem (Muthukumaraswamy et al., 2021).

translation

Ritual borrowing: some clinics adopt Indigenous language, music or plant-medicine aesthetics while operating through proprietary, biomedical systems. Scholarship asks who is credited, compensated and authorised, and whether “set and setting” is being detached from the communities that sustained it (Gukasyan and Nayak, 2022).

safety

Adverse experience and aftercare: acute fear, hypertension, nausea, dissociation, suicidality, manic or psychotic destabilisation, exploitation and delayed distress require compound-specific screening and longitudinal support. A comforting room is not a substitute for clinical governance.

Linked species and complexes

Linked species page

Psilocybe spp.

Fungal ecology, psilocybin chemistry and ceremonial histories beyond the synthetic clinical product.

Linked neo-psychedelic page

Ketamine

Anaesthetic history, trace natural occurrence claims, Lilly’s technological phenomenology, KPT, KAP and clinic culture.

Linked compound page

MDMA

Entactogenic pharmacology, dance cultures, underground therapy and pharmaceutical development.

Comparative complex

Ayahuasca and neo-shamanic clinics

Alternative relations among sacrament, guide, music, community, diagnosis and law.

Comparative complex

Bwiti–Iboga and ibogaine treatment

Initiatory religion, detoxification clinics and the contested translation of visionary ordeal into treatment.

Comparative framework

Neo-Psychedelics

Synthetic compounds acquiring sacramental, therapeutic and self-technological status in modern institutions.

Bibliography

Harvard style (Cite Them Right) · DOI and stable-record links · 50 sources

Archaeology & history

01 · 9 sources
Dyck, E. (2005) ‘Flashback: psychiatric experimentation with LSD in historical perspective’, Canadian Journal of Psychiatry, 50(7), pp. 381–388. Available at: https://doi.org/10.1177/070674370505000703.
DOI checked
Open record ↗
Fadiman, J. (2003) ‘Psychedelic research revisited’, Journal of Transpersonal Psychology, 35(2), pp. 111–125. Available at: Association for Transpersonal Psychology.
journal PDF
Open record ↗
Grof, S. (1980) LSD Psychotherapy. Pomona, CA: Hunter House.
historical monograph
Lilly, J.C. (1972) Programming and Metaprogramming in the Human Biocomputer: Theory and Experiments. New York: Julian Press.
historical primary text
Oram, M. (2016) ‘Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration’, History of Psychiatry, 27(3), pp. 290–306. Available at: https://doi.org/10.1177/0957154X16648822.
DOI checked
Open record ↗
Passie, T. (2018) ‘The early use of MDMA (“Ecstasy”) in psychotherapy (1977–1985)’, Drug Science, Policy and Law, 4, pp. 1–19. Available at: https://doi.org/10.1177/2050324518767442.
DOI checked
Open record ↗
Stolaroff, M.J. (2004) The Secret Chief Revealed: Conversations with Leo Zeff, Pioneer in the Underground Psychedelic Therapy Movement. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies.
oral history
Williams, J. (2019) ‘“You are entering a new dimension”: John C. Lilly, the sensory isolation tank and the counterculture’, History of the Human Sciences, 32(5), pp. 3–26. Available at: https://doi.org/10.1177/0952695119872094.
DOI checked
Open record ↗
Yensen, R. and Dryer, D. (1992) ‘Thirty years of psychedelic research: the Spring Grove experiment and its sequels’, Yearbook of the European College for the Study of Consciousness, 1991–1992, pp. 73–102.
historical review

Clinical research & neuroscience

02 · 20 sources
Berman, R.M., Cappiello, A., Anand, A. et al. (2000) ‘Antidepressant effects of ketamine in depressed patients’, Biological Psychiatry, 47(4), pp. 351–354. Available at: https://doi.org/10.1016/S0006-3223(99)00230-9.
DOI checked
Open record ↗
Brennan, W., Belser, A.B., Swift, T.C. et al. (2022) ‘Development of EMBARK: a transdiagnostic, trans-drug model for the provision of psychological support for psychedelic therapy’, Frontiers in Psychology, 13, 866018. Available at: https://doi.org/10.3389/fpsyg.2022.866018.
DOI checked
Open record ↗
Carhart-Harris, R., Giribaldi, B., Watts, R. et al. (2021) ‘Trial of psilocybin versus escitalopram for depression’, New England Journal of Medicine, 384, pp. 1402–1411. Available at: https://doi.org/10.1056/NEJMoa2032994.
DOI checked
Open record ↗
COMPASS Pathways (2026a) ‘COMPASS Pathways successfully achieves primary endpoint in second Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression’, 17 February. Available at: COMPASS investor relations (Accessed: 29 July 2026).
corporate topline
Open record ↗
COMPASS Pathways (2026b) ‘Six-month data from second Phase 3 trial confirming rapid and durable profile’, 7 July. Available at: COMPASS investor relations (Accessed: 29 July 2026).
corporate topline
Open record ↗
Davis, A.K., Barrett, F.S., May, D.G. et al. (2021) ‘Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial’, JAMA Psychiatry, 78(5), pp. 481–489. Available at: https://doi.org/10.1001/jamapsychiatry.2020.3285.
DOI checked
Open record ↗
Dore, J., Turnipseed, B., Dwyer, S. et al. (2019) ‘Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy’, Journal of Psychoactive Drugs, 51(2), pp. 189–198. Available at: https://doi.org/10.1080/02791072.2019.1587556.
DOI checked
Open record ↗
Drożdż, S.J., Goel, A., McGarr, M.W. et al. (2022) ‘Ketamine assisted psychotherapy: a systematic narrative review of the literature’, Journal of Pain Research, 15, pp. 1691–1706. Available at: https://doi.org/10.2147/JPR.S360733.
DOI checked
Open record ↗
Goodwin, G.M., Aaronson, S.T., Alvarez, O. et al. (2022) ‘Single-dose psilocybin for a treatment-resistant episode of major depression’, New England Journal of Medicine, 387, pp. 1637–1648. Available at: https://doi.org/10.1056/NEJMoa2206443.
DOI checked
Open record ↗
Griffiths, R.R., Richards, W.A., McCann, U. and Jesse, R. (2006) ‘Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance’, Psychopharmacology, 187, pp. 268–283. Available at: https://doi.org/10.1007/s00213-006-0457-5.
DOI checked
Open record ↗
Kolp, E., Friedman, H.L., Krupitsky, E., Jansen, K., Sylvester, M., Young, M.S. and Kolp, A. (2014) ‘Ketamine psychedelic psychotherapy: focus on its pharmacology, phenomenology, and clinical applications’, International Journal of Transpersonal Studies, 33(2), pp. 84–140. Available at: https://doi.org/10.24972/ijts.2014.33.2.84.
DOI checked
Open record ↗
Krupitsky, E., Burakov, A., Romanova, T. et al. (2007) ‘Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence’, Journal of Psychoactive Drugs, 39(1), pp. 13–19. Available at: https://doi.org/10.1080/02791072.2007.10399860.
DOI checked
Open record ↗
Krupitsky, E.M. and Grinenko, A.Y. (1997) ‘Ketamine psychedelic therapy (KPT): a review of the results of ten years of research’, Journal of Psychoactive Drugs, 29(2), pp. 165–183. Available at: https://doi.org/10.1080/02791072.1997.10400185.
DOI checked
Open record ↗
Krystal, J.H., Abdallah, C.G., Sanacora, G. et al. (2023) ‘Ketamine: a paradigm shift for depression research and treatment’, Proceedings of the National Academy of Sciences, 120(49), e2305772120. Available at: https://doi.org/10.1073/pnas.2305772120.
DOI checked
Open record ↗
Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. (2021) ‘MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled Phase 3 study’, Nature Medicine, 27, pp. 1025–1033. Available at: https://doi.org/10.1038/s41591-021-01336-3.
DOI checked
Open record ↗
Mitchell, J.M., Ot’alora, G.M., van der Kolk, B. et al. (2023) ‘MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled Phase 3 trial’, Nature Medicine, 29, pp. 2473–2480. Available at: https://doi.org/10.1038/s41591-023-02565-4.
DOI checked
Open record ↗
Mithoefer, M.C. (2017) A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder. Version 8.1. Santa Cruz, CA: MAPS. Available at: MAPS.
protocol manual
Open record ↗
Simpson, R.J., Juruena, M.F. et al. (2026) ‘Effectiveness of ketamine-assisted psychotherapy as a treatment for depression: a systematic review’, Psychopharmacology. Available at: https://doi.org/10.1007/s00213-026-07003-0.
DOI checked
Open record ↗
Wolfgang, A.S., Fonzo, G.A., Gray, J.C. et al. (2025) ‘MDMA and MDMA-assisted therapy’, American Journal of Psychiatry, 182(1), pp. 79–103. Available at: https://doi.org/10.1176/appi.ajp.20230681.
DOI checked
Open record ↗
Zarate, C.A. Jr, Singh, J.B., Carlson, P.J. et al. (2006) ‘A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression’, Archives of General Psychiatry, 63(8), pp. 856–864. Available at: https://doi.org/10.1001/archpsyc.63.8.856.
DOI checked
Open record ↗

Ethnography, ritual & cosmology

03 · 11 sources
Bender, D.A., Nayak, S.M., Siegel, J.S. et al. (2025) ‘The role of touch in psychedelic therapy: perspectives from a survey of practitioners in research settings’, American Journal of Psychotherapy, 78(4). Available at: https://doi.org/10.1176/appi.psychotherapy.20240025.
DOI checked
Open record ↗
Bonny, H.L. and Pahnke, W.N. (1972) ‘The use of music in psychedelic (LSD) psychotherapy’, Journal of Music Therapy, 9(2), pp. 64–87. Available at: https://doi.org/10.1093/jmt/9.2.64.
DOI checked
Open record ↗
Dumit, J. and Sanabria, E. (2022) ‘Set, setting, and clinical trials: colonial technologies and psychedelics experiment’, in Bruun, M.H., Wahlberg, A., Douglas-Jones, R., Hasse, C., Hoeyer, K., Kristensen, D.B. and Winthereik, B.R. (eds) The Palgrave Handbook of the Anthropology of Technology. Singapore: Palgrave Macmillan, pp. 291–308. Available at: https://doi.org/10.1007/978-981-16-7084-8_15.
chapter DOI checked
Open record ↗
Frymann, T., Whitney, S., Yaden, D.B. and Lipson, J. (2022) ‘The Psychedelic Integration Scales: tools for measuring psychedelic integration behaviors and experiences’, Frontiers in Psychology, 13, 863247. Available at: https://doi.org/10.3389/fpsyg.2022.863247.
DOI checked
Open record ↗
Gukasyan, N. and Nayak, S.M. (2022) ‘Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy’, Transcultural Psychiatry, 59(5), pp. 652–664. Available at: https://doi.org/10.1177/1363461520983684.
DOI checked
Open record ↗
Hartogsohn, I. (2017) ‘Constructing drug effects: a history of set and setting’, Drug Science, Policy and Law, 3, pp. 1–17. Available at: https://doi.org/10.1177/2050324516683325.
DOI checked
Open record ↗
Johnson, M.W., Richards, W.A. and Griffiths, R.R. (2008) ‘Human hallucinogen research: guidelines for safety’, Journal of Psychopharmacology, 22(6), pp. 603–620. Available at: https://doi.org/10.1177/0269881108093587.
DOI checked
Open record ↗
Kaelen, M., Giribaldi, B., Raine, J. et al. (2018) ‘The hidden therapist: evidence for a central role of music in psychedelic therapy’, Psychopharmacology, 235, pp. 505–519. Available at: https://doi.org/10.1007/s00213-017-4820-5.
DOI checked
Open record ↗
MacLean, K.A., Leoutsakos, J.-M.S., Johnson, M.W. and Griffiths, R.R. (2012) ‘Factor analysis of the Mystical Experience Questionnaire: a study of experiences occasioned by the hallucinogen psilocybin’, Journal for the Scientific Study of Religion, 51(4), pp. 721–737. Available at: https://doi.org/10.1111/j.1468-5906.2012.01685.x.
DOI checked
Open record ↗
Muthukumaraswamy, S.D., Forsyth, A. and Lumley, T. (2021) ‘Blinding and expectancy confounds in psychedelic randomized controlled trials’, Expert Review of Clinical Pharmacology, 14(9), pp. 1133–1152. Available at: https://doi.org/10.1080/17512433.2021.1933434.
DOI checked
Open record ↗
Nour, M.M., Evans, L., Nutt, D. and Carhart-Harris, R.L. (2016) ‘Ego-dissolution and psychedelics: validation of the Ego-Dissolution Inventory (EDI)’, Frontiers in Human Neuroscience, 10, 269. Available at: https://doi.org/10.3389/fnhum.2016.00269.
DOI checked
Open record ↗

Law, policy & patents

04 · 10 sources
Drabiak, K. (2025) ‘Caution is warranted in prescribing ketamine for mental health conditions’, Journal of General Internal Medicine. Available at: https://doi.org/10.1007/s11606-025-10024-8.
DOI checked
Open record ↗
Gerber, K., Flores, I.G., Ruiz, A.C. and Ali, I. (2021) ‘Ethical concerns about psilocybin intellectual property’, ACS Pharmacology & Translational Science, 4(2), pp. 573–577. Available at: https://doi.org/10.1021/acsptsci.0c00171.
DOI checked
Open record ↗
Marks, M. (2021) ‘Patents on psychedelics: the next legal battlefront of drug development’, Harvard Law Review Forum, 135. Available at: Harvard Law Review (Accessed: 29 July 2026).
law review
Open record ↗
Oregon Health Authority (OHA) (2023) Oregon Psilocybin Services fact sheet. Available at: OHA (Accessed: 29 July 2026).
official programme
Open record ↗
Therapeutic Goods Administration (TGA) (2026) ‘MDMA and psilocybine hub’ and ‘Updates to Authorised Prescriber scheme requirements’, updated 26 May. Available at: TGA (Accessed: 29 July 2026).
official programme
Open record ↗
US Food and Drug Administration (FDA) (2019) Spravato Risk Evaluation and Mitigation Strategy. Available at: FDA (Accessed: 29 July 2026).
official REMS
Open record ↗
US Food and Drug Administration (FDA) (2023) ‘FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders’, 10 October. Available at: FDA (Accessed: 29 July 2026).
official safety alert
Open record ↗
US Food and Drug Administration (FDA) (2024a) Complete Response Letter: NDA 215455, midomafetamine capsules, 8 August. Available at: FDA (Accessed: 29 July 2026).
official decision letter
Open record ↗
US Food and Drug Administration (FDA) (2024b) Psychopharmacologic Drugs Advisory Committee briefing document: NDA 215455, 4 June. Available at: FDA (Accessed: 29 July 2026).
official review
Open record ↗
US Food and Drug Administration (FDA) (2025) Spravato (esketamine) nasal spray: prescribing information. Available at: FDA (Accessed: 29 July 2026).
official label
Open record ↗